Age-Specific Ovarian Cancer Risk Among Individuals With Pathogenic Variants in PALB2.

Authors

Koki Takabatake, Nicolas Kubista, Maria Sol Rosito, Yue Zhang, Stephen B Gruber, Gregory Idos, Giovanni Parmigiani, Danielle Braun, Clinical Cancer Genomics Cancer Research Network

Published in

JCO precision oncology. Volume 10. Issue 8. Pages e2600167. Epub Aug 26, 2026.

Abstract

Pathogenic germline variants (PGVs) in PALB2 are well-established risk factors for breast cancer, but their association with ovarian cancer (OC) remains less characterized. This study estimates age-specific OC risk among PALB2 PGV carriers using a Bayesian segregation analysis approach.
Family history, including OC diagnoses, was collected from probands with PGVs in PALB2 from the Clinical Cancer Genomics Cancer Research Network (CCGCRN). CCGCRN is a consortium of 31 active community-based oncogenetic practices across 50 states in the United States and four countries in Latin America. A total of 140 probands with PGVs in PALB2 were identified in CCGCRN, and family history was reported on 5,188 relatives (average family size is 38 individuals). Overall, 30 women had OC; of these, 5 cases were among probands and the remaining were among reported relatives. Age-specific penetrance of OC was estimated using the penetrance R package that employs a parametric Bayesian segregation analysis estimation approach, leveraging the family history.
The cumulative lifetime risk for OC for female carriers of PALB2 PGVs at age 80 years was estimated to be 5.38% (95% CI [2.94 to 8.26]). This is significantly greater than the general population risk of 1.10% from the SEER data.
We estimated a significantly increased risk of OC among individuals with PALB2 PGVs compared with the SEER general population. However, our estimated credible interval was wide, likely because of the small sample number of probands and small number of OC cases. Further studies should continue to explore the association between PGVs in PALB2 and OC risk.

PMID:
42647764
Bibliographic data and abstract were imported from PubMed on 27 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.